DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
11	重症筋無力症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04226170 (ClinicalTrials.gov)	September 30, 2020	9/1/2020	Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis	A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given With Ondansetron to Subjects With Anti-AchR Positive Myasthenia Gravis	Myasthenia Gravis	Drug: DAS-001	DAS-MG, Inc	NULL	Not yet recruiting	18 Years	N/A	All	24	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04226170
(ClinicalTrials.gov)

September 30, 2020

9/1/2020

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given With Ondansetron to Subjects With Anti-AchR Positive Myasthenia Gravis

Myasthenia Gravis

Drug: DAS-001

DAS-MG, Inc

NULL

Not yet recruiting

18 Years

N/A

All

Phase 2

United States